DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.81

Change

-0.01 (-0.11)%

Market Cap

USD 0.17B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.11 (+0.11%)

USD 16.41B
IVV:AU iShares Core S&P 500 AUD

+0.01 (+0.02%)

USD 8.73B
VGS:AU Vanguard MSCI International Sh..

+0.25 (+0.20%)

USD 8.59B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.12 (+0.22%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

+0.04 (+0.12%)

USD 6.15B
STW:AU SPDR® S&P/ASX 200 Fund

+0.05 (+0.07%)

USD 5.62B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.05 (+0.13%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

+0.21 (+0.49%)

USD 4.83B
A200:AU BetaShares Australia 200

+0.13 (+0.09%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+1.53 (+0.38%)

USD 4.70B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.24% 68% D+ 70% C-
Dividend Return 3.15% 53% F 46% F
Total Return 14.39% 71% C- 70% C-
Trailing 12 Months  
Capital Gain 14.71% 49% F 66% D+
Dividend Return 3.25% 44% F 36% F
Total Return 17.97% 48% F 66% D+
Trailing 5 Years  
Capital Gain 51.90% 86% B+ 77% C+
Dividend Return 11.10% 47% F 35% F
Total Return 62.99% 85% B 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.95% N/A N/A 58% F
Dividend Return 8.50% N/A N/A 57% F
Total Return 1.56% N/A N/A 31% F
Risk Return Profile  
Volatility (Standard Deviation) 8.39% N/A N/A 93% A
Risk Adjusted Return 101.31% N/A N/A 98% N/A
Market Capitalization 0.17B 34% F 66% D+

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.